222

EUTILEX CO., LTD.

No trades
See on Supercharts

263050 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Eutilex Co., Ltd. develops anti-tumor T cell therapy and antibody therapeutics based on proprietary immunotherapy technology. It offers T Cell Therapy, Antibody, CAR-T Cell Therapy. The company was founded by Kwon Byoung S on February 27, 2015 and is headquartered in Seoul, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

263050 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company